甲状腺疾患治療市場規模、シェア、成長分析：タイプ別、薬剤別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

甲状腺疾患治療市場規模は2023年に26億米ドルと評価され、2024年の27億米ドルから2032年には37億米ドルに成長し、予測期間（2025-2032年）のCAGRは4.0％で成長する見通しです。

甲状腺疾患治療の世界市場は、高齢化、医療技術の進歩、早期診断・治療に対する意識の高まりによって、甲状腺機能亢進症のような疾患の発生率が上昇しているため、著しい成長を遂げています。革新的な個別化医療と標的療法が登場し、有病率とヘルスケア支出が高い北米と欧州を主要市場として位置づけています。ラテンアメリカとアジア太平洋の新興国は、ヘルスケアインフラの改善と意識の高まりに後押しされ、大きな成長機会をもたらしています。遠隔医療も普及しつつあり、内分泌学サービスへの患者アクセスを高めています。限られた診断施設や高額な治療費といった課題にもかかわらず、甲状腺疾患治療市場の全体的な見通しは依然として良好であり、今後数年間の回復力と継続的な拡大を示唆しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ

甲状腺疾患治療市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 甲状腺機能低下症
• 甲状腺機能亢進症

甲状腺疾患治療市場規模：薬剤別& CAGR（2025-2032）

• 市場概要
• レボチロキシン
• リオチロニン
• プロピルチオウラシル
• イミダゾール系化合物
• その他

甲状腺疾患治療市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 静脈
• その他

甲状腺疾患治療市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 卸売販売
• 小売店
• オンライン薬局
• その他

甲状腺疾患治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• GSK Plc（UK）
• Merck KGaA（Germany）
• Viatris Inc.（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Exelixis Inc.（USA）
• Abbott Laboratories（USA）
• Fresenius SE & Co. KGaA（Germany）
• Jerome Stevens Pharmaceuticals Inc.（USA）
• Lannett Co. Inc.（USA）

結論と提言

Thyroid Gland Disorders Treatment Market size was valued at USD 2.6 billion in 2023 and is poised to grow from USD 2.7 billion in 2024 to USD 3.7 billion by 2032, growing at a CAGR of 4.0% during the forecast period (2025-2032).

The global market for thyroid gland disorder treatments has seen remarkable growth due to the rising incidence of conditions like hyperthyroidism, driven by an aging population, advancements in medical technology, and heightened awareness of early diagnosis and treatment. Innovative personalized medicine and targeted therapies have emerged, positioning North America and Europe as key markets due to higher prevalence rates and healthcare expenditures. Emerging economies in Latin America and Asia-Pacific present significant growth opportunities, fueled by improved healthcare infrastructure and increased awareness. Telemedicine is also gaining traction, enhancing patient access to endocrinology services. Despite challenges such as limited diagnostic facilities and high treatment costs, the overall outlook for the thyroid disorder treatment market remains positive, suggesting resilience and continued expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Thyroid Gland Disorders Treatment Market Segments Analysis

Global Thyroid Gland Disorders Treatment Market is segmented by Type, Drug, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Hypothyroidism and Hyperthyroidism. Based on Drug, the market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Others. Based on Distribution Channel, the market is segmented into Wholesale Distribution, Retail Stores, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Thyroid Gland Disorders Treatment Market

The global prevalence of thyroid disorders, including hyperthyroidism, hypothyroidism, and various forms of thyroid cancer, is on the rise, largely due to increasing mental stress and changing lifestyle factors. Environmental influences have also contributed to the surge in these conditions, leading to a greater need for effective treatments. Consequently, the market for thyroid gland disorder treatments has expanded significantly to accommodate the growing patient population seeking specialized medical care for their conditions. This escalating demand is driving innovation and investment in therapeutic options, underscoring the importance of addressing thyroid health in today's world.

Restraints in the Thyroid Gland Disorders Treatment Market

The pricey nature of prescription medications significantly impacts patients undergoing long-term treatment for thyroid disorders, creating a considerable barrier. Therapeutic options, such as radioactive iodine therapy and surgical interventions, often incur substantial costs, which can be prohibitive for many individuals. This challenge is especially pronounced for those residing in regions with limited healthcare access or inadequate health insurance coverage, making these essential treatments a major financial strain. Consequently, the high expenses associated with thyroid gland disorder therapies can hinder patients from receiving timely and necessary medical attention, ultimately affecting their overall health and well-being.

Market Trends of the Thyroid Gland Disorders Treatment Market

The thyroid gland disorders treatment market is experiencing significant growth propelled by rising incidence rates worldwide. This trend has prompted pharmaceutical companies to intensify their research and development efforts, resulting in advanced treatment options that cater to an expanding patient population. Key market players are focused on innovation, striving to develop more effective and affordable therapies. These innovations not only aim to enhance overall patient outcomes but also prioritize minimizing side effects and improving quality of life. As a result, the market is poised for sustained growth, reflecting a proactive response to the increasing need for effective thyroid disorder management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Thyroid Gland Disorders Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hypothyroidism
• Hyperthyroidism

Global Thyroid Gland Disorders Treatment Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based compounds
• Others

Global Thyroid Gland Disorders Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Others

Global Thyroid Gland Disorders Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Wholesale Distribution
• Retail Stores
• Online Pharmacy
• Others

Global Thyroid Gland Disorders Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drug, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations